Evidence map›Paper›PMID 30848403›Full record

Trial reportInvestigational new drugs2019

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Katsuhiko Okubo, Takashi Nakakuma, Hirofumi Yamada, Kei Kimizuka, Tohru Higuchi, SBCCSG-36 investigators

Erratum issuedAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Kenichi InoueDivision of Breast Oncology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita-adachi-gun, Saitama, 362-0806, Japan. ino.bad.ken@gmail.com.ORCID 0000-0003-2686-8732
Jun NinomiyaDepartment of Breast Surgery, Ninomiya Hospital, Soka, Japan.
Tsuyoshi SaitoDepartment of Breast Surgery, Saitama Red Cross Hospital, Saitama, Japan.
Katsuhiko OkuboDepartment of Breast Unit, Toda Central General Hospital, Saitama, Japan.
Takashi NakakumaDepartment of Breast Surgery, Ageo Central General Hospital, Ageo, Japan.
Hirofumi YamadaDepartment of Surgery, Sekishindo Hospital, Saitama, Japan.
Kei KimizukaDepartment of Breast Surgery, Kasukabe Medical Center, Kasukabe, Japan.
Tohru HiguchiDepartment of Breast Surgery, Saitama Red Cross Hospital, Saitama, Japan.
SBCCSG-36 investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose To examine the efficacy and safety of triple therapy with eribulin, trastuzumab, and pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) who never received any prior therapy in the first-line metastatic/advanced setting. Methods Eribulin 1.4 mg/m

Indexed as

AdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesFuransHumansKetonesMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisNeoplasm Recurrence, LocalPolyether PolyketidesAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinaseseribulinFuransKetonespertuzumabPolyether PolyketidesTrastuzumabEribulinFirst-line therapyHER2-positiveMetastatic breast cancerPertuzumabTrastuzumab

Identifiers

PMID30848403
PMCPMC6538821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.